Evidence map›Paper›PMID 40046757›Full record

ArticleFrontiers in nutrition2025

Sex-specific prognostic utility of the sarcopenia index in all-cause mortality risk for patients with heart failure.

Ming Li, Yanying Liang, Baozhen Wu, Ziliang Zhu, Meifang Wang, Jianying Chen, Can Chen

Abstract read
In one paragraph

Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ming LiThe First Clinical Medical College, Jinan University, Guangzhou, China.
Yanying LiangDepartment of Cardiology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Baozhen WuDepartment of Cardiology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Ziliang ZhuDepartment of Cardiology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Meifang WangDepartment of Cardiology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Jianying ChenDepartment of Cardiology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Can ChenThe First Clinical Medical College, Jinan University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The sarcopenia index (SI), derived from serum creatinine and cystatin C levels, has emerged as a novel and accessible biomarker for predicting clinical outcomes. However, its sex-specific prognostic utility in heart failure (HF) remains poorly understood. This study aimed to investigate the association between SI and all-cause mortality in HF, with a focus on sex-specific differences. Methods: A retrospective cohort of 753 patients (median age: 69 years; 61% male) diagnosed with HF from a tertiary hospital in China was analyzed. Cox regression models and Kaplan-Meier survival analyses were utilized to evaluate the relationship between SI and all-cause mortality. Stratified analyses based on sex were performed, and the incremental predictive value of SI was assessed by integrating it into traditional risk models. Results: Over a median follow-up of 537 days, 143 deaths occurred. In adjusted models, a lower SI was significantly associated with an increased risk of all-cause mortality in male patients (hazard ratio: 0.98 per unit increase, 95% confidence interval: 0.97-0.99, Conclusion: The SI serves as a robust sex-specific predictor of all-cause mortality in HF, demonstrating significant prognostic value in males but limited utility in females. These findings highlight the potential of SI as a cost-effective addition to existing risk stratification models for male patients with HF.

Indexed as

all-cause mortalityheart failureprognostic biomarkersarcopenia indexsex-specific differences

Identifiers

PMID40046757
PMCPMC11879831

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.